Vaxcyte, Inc. (NASDAQ:PCVX) Shares Bought by Citigroup Inc.

Citigroup Inc. boosted its holdings in shares of Vaxcyte, Inc. (NASDAQ:PCVX - Free Report) by 33.0% in the third quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 220,543 shares of the company's stock after buying an additional 54,748 shares during the quarter. Citigroup Inc. owned 0.18% of Vaxcyte worth $25,201,000 at the end of the most recent reporting period.

A number of other institutional investors also recently bought and sold shares of PCVX. O Shaughnessy Asset Management LLC purchased a new position in Vaxcyte during the 1st quarter worth approximately $321,000. CANADA LIFE ASSURANCE Co increased its holdings in shares of Vaxcyte by 163.5% during the 1st quarter. CANADA LIFE ASSURANCE Co now owns 18,064 shares of the company's stock valued at $1,234,000 after purchasing an additional 11,208 shares in the last quarter. Bayesian Capital Management LP purchased a new position in shares of Vaxcyte during the 1st quarter valued at approximately $412,000. Kennedy Capital Management LLC purchased a new position in shares of Vaxcyte during the 1st quarter valued at approximately $258,000. Finally, California State Teachers Retirement System increased its holdings in Vaxcyte by 11.8% in the 1st quarter. California State Teachers Retirement System now owns 92,026 shares of the company's stock worth $6,286,000 after acquiring an additional 9,695 shares in the last quarter. 96.78% of the stock is owned by hedge funds and other institutional investors.

Vaxcyte Price Performance

Shares of PCVX opened at $91.45 on Wednesday. Vaxcyte, Inc. has a 1 year low of $48.35 and a 1 year high of $121.06. The company's 50-day simple moving average is $106.93 and its 200-day simple moving average is $89.94.

Vaxcyte (NASDAQ:PCVX - Get Free Report) last issued its quarterly earnings results on Tuesday, November 5th. The company reported ($0.83) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.10) by $0.27. During the same quarter last year, the firm posted ($0.91) EPS. As a group, sell-side analysts anticipate that Vaxcyte, Inc. will post -4.14 earnings per share for the current fiscal year.

Insider Transactions at Vaxcyte

In related news, SVP Elvia Cowan sold 5,000 shares of the firm's stock in a transaction that occurred on Tuesday, September 3rd. The shares were sold at an average price of $107.67, for a total value of $538,350.00. Following the sale, the senior vice president now owns 12,723 shares of the company's stock, valued at $1,369,885.41. This trade represents a 28.21 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CFO Andrew Guggenhime sold 8,000 shares of the firm's stock in a transaction that occurred on Wednesday, September 18th. The shares were sold at an average price of $115.94, for a total transaction of $927,520.00. Following the completion of the sale, the chief financial officer now directly owns 90,383 shares in the company, valued at approximately $10,479,005.02. This trade represents a 8.13 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 102,464 shares of company stock valued at $11,455,576. 3.10% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently issued reports on PCVX shares. Cantor Fitzgerald reaffirmed an "overweight" rating on shares of Vaxcyte in a report on Wednesday, November 6th. Leerink Partners increased their target price on shares of Vaxcyte from $106.00 to $153.00 and gave the stock an "outperform" rating in a research note on Tuesday, September 3rd. Needham & Company LLC reaffirmed a "buy" rating and set a $140.00 target price on shares of Vaxcyte in a research note on Wednesday, November 6th. Bank of America increased their target price on shares of Vaxcyte from $101.00 to $140.00 and gave the stock a "buy" rating in a research note on Wednesday, September 4th. Finally, Mizuho increased their target price on shares of Vaxcyte from $113.00 to $163.00 and gave the stock an "outperform" rating in a research note on Tuesday, September 10th. Seven research analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock has an average rating of "Buy" and a consensus price target of $147.50.

Vaxcyte Profile

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.